• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PureTech Proposes $100 Million Capital Return

    3/19/24 3:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email

    Proposed capital return of $100 million by way of a Tender Offer at 250 pence per Ordinary Share

    Premium of 25% to PureTech's trailing three-day VWAP

    Proposed Tender Offer follows completion of Karuna Therapeutics' $14 billion acquisition by Bristol Myers Squibb. The Tender Offer will be launched following publication of the Company's Full Year Results in April 2024

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces a proposed capital return of $100 million to its shareholders by way of a tender offer (the "Tender Offer"). The capital return of $100 million represents approximately 14% of PureTech's market capitalization based on yesterday's closing price. This follows the Company's announcement that it will receive approximately $293 million gross proceeds from its remaining stake in Karuna.

    The Tender Offer will be launched after the publication of the Company's Full Year Results in April 2024, subject to market conditions, and will require shareholder approval. A circular setting out the full terms of the Tender Offer and a timetable will be published upon launch.

    If the full $100 million is not returned, then the Company intends to return any remainder following the completion of the Tender Offer, by way of a special dividend.

    Daphne Zohar, PureTech Founder and Chief Executive Officer commented:

    "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14 billion is a testament to our execution on both fronts. We directed $18.5 million to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1 billion in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years. We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50 million share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline – as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

    As noted on 8 February 2024, the Company recently completed a $50 million Share Buyback Program, which – together with the proposed Tender Offer – would constitute $150 million of capital returned to shareholders, which is approximately 21% of the Company's market capitalization as of 18 March 2024.

    The Board determined the amount of the Tender Offer after considering feedback from a number of shareholders, tax implications, and the continued support of the Company's existing and future Programs, including the recently announced Founded Entities. PureTech aims to maintain at least three year's cash runway, and the Board intends to evaluate its capital allocation policy regularly to assess opportunities for additional capital returns to shareholders, subject to the Company's operational needs.

    About PureTech Health

    PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 28 therapeutics and therapeutic candidates, including two that have received both US FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

    For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

    Additional Information for U.S. Investors

    The Tender Offer has not yet been approved by the Company's shareholders and, accordingly, has not yet commenced. This communication is provided for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of the Company pursuant to the Tender Offer or otherwise. If the Tender Offer is approved by the Company's shareholders and does not qualify as a Tier I offer within the meaning of Rule 13e-4(h)(8) under the Securities Exchange Act of 1934, as amended, Company intends to file a tender offer statement on Schedule TO and related materials with the SEC in respect of such Tender Offer. The Company's security holders are advised to carefully read these documents if and when they become available, and any amendments to these documents, in their entirety before making any decision with respect to the Tender Offer, because these documents will contain important information. If and when filed, the Company's security holders may obtain copies of these documents and other documents filed with the SEC for free at the SEC's website at www.sec.gov. In addition, if and when filed, the Company will provide copies of such documents free of charge to its security holders.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our future prospects, developments, and strategies, and statements regarding the intent, belief or current expectations regarding the intended commencement of the Tender Offer. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.

    THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240319883260/en/

    Get the next $PRTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

      Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings highlight the profound physical, emotional, and psychosocial burden of IPF and underscore urgent need for enhanced education, streamlined diagnosis, patient-focused treatment plans, and more effective therapies PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the publication of new research in BMC Pulmonary Medicine that provides a comprehensive

      5/9/25 7:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

      Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will deliver a late-breaking oral presentation at the upcoming American Thoracic Society (ATS) International Conference, taking place in San Francisco, California, from May 16-21, 2025.

      5/1/25 7:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Announces Annual Results for Year Ended December 31, 2024

      Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

      4/30/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners resumed coverage on PureTech Health plc with a new price target

      Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

      9/9/24 7:42:36 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on PureTech Health with a new price target

      SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

      1/7/22 4:34:06 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on PureTech Health with a new price target

      SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

      8/25/21 4:40:14 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PureTech Health plc

      SC 13G - PureTech Health plc (0001782999) (Subject)

      11/12/24 1:29:13 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PureTech Health plc

      SC 13G/A - PureTech Health plc (0001782999) (Subject)

      11/7/24 9:47:57 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

      SC 13G/A - PureTech Health plc (0001782999) (Subject)

      2/12/24 4:48:30 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Financials

    Live finance-specific insights

    See more
    • PureTech Health: Notice of Results

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

      4/23/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

      Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo De

      12/16/24 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Appoints Peel Hunt as Joint UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

      4/9/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • PureTech Appoints UBS as UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, includ

      1/6/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    SEC Filings

    See more
    • SEC Form 20-F filed by PureTech Health plc

      20-F - PureTech Health plc (0001782999) (Filer)

      4/30/25 10:43:35 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PureTech Health plc

      6-K - PureTech Health plc (0001782999) (Filer)

      4/30/25 6:30:13 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PureTech Health plc

      6-K - PureTech Health plc (0001782999) (Filer)

      4/7/25 4:15:13 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care